Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders
2014 (English)In: Immunotherapy, ISSN 1750-743X, Vol. 6, no 2, 141-153 p.Article, review/survey (Refereed) Published
Immunotherapy targeting a-synuclein has evolved as a potential therapeutic strategy for neurodegenerative diseases, such as Parkinson's disease, and initial studies on cellular and animal models have shown promising results. alpha-synuclein vaccination of transgenic mice reduced the number of brain inclusions, whereas passive immunization studies demonstrated that antibodies against the C-terminus of alpha-synuclein can pass the blood-brain barrier and affect the pathology. In addition, preliminary evidence suggests that transgenic mice treated with an antibody directed against alpha-synuclein oligomers/protofibrils resulted in reduced levels of such species in the CNS. The underlying mechanisms of immunotherapy are not yet fully understood, but may include antibody-mediated clearance of pre-existing aggregates, prevention of protein propagation between cells and microglia-dependent protein clearance. Thus, immunotherapy targeting alpha-synuclein holds promise, but needs to be further developed as a future disease-modifying treatment in Parkinson's disease and other alpha-synucleinopathies.
Place, publisher, year, edition, pages
2014. Vol. 6, no 2, 141-153 p.
alpha-synuclein, antibody, immunization, immunotherapy, Parkinson's disease
Immunology in the medical area
IdentifiersURN: urn:nbn:se:uu:diva-229388DOI: 10.2217/IMT.13.162ISI: 000337967400011OAI: oai:DiVA.org:uu-229388DiVA: diva2:736420